Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (NASDAQ: AAPG) reported unaudited results for the six months ended June 30, 2026, with revenue rising 29% year-over-year on a constant currency basis to US$44.5 million (RMB302.2 million), driven by a 32.6% increase in product sales to US$41.6 million. Gross profit reached RMB290.5 million (US$42.8 million).
Operating expenses expanded significantly: selling and distribution expenses grew 64.3% to US$33.4 million, research and development expenses increased 32.0% to US$102.8 million, and administrative expenses rose 19.3% to US$17.5 million. Loss for the period widened to US$120.4 million, or US$0.32 per share. Cash and bank balances were US$279.4 million, down from US$353.2 million at year-end 2025, mainly due to higher R&D spending.
The company highlighted commercial expansion of Olverembatinib and Lisaftoclax in China and progress across nine registrational Phase III trials, plus FDA and China CDE IND clearances for BTK degrader APG-3288. New Chief Business and Chief Commercial Officers were appointed, and the “B” marker was removed from its HKEX short name.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) announced that its management will participate in the Evercore ISI 2nd Annual China Biotech Summit, held on August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong. The team will join a fireside chat and hold one-on-one investor meetings.
The fireside chat is scheduled for August 18, 2026, from 7:45-8:00am Beijing Time, in Grand Ballroom 2 & 3. Investors can arrange meetings with management through their Evercore representative.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) corrected the timing of its upcoming disclosure, stating it will release unaudited six-month 2026 interim results and provide a corporate update at 7:00 am EDT / 7:00 pm HKT on August 19, 2026. The company will host a Mandarin investor webcast at 9:00 pm EDT on August 19 / 9:00 am HKT on August 20, 2026, and an English investor conference call and webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026, with advance registration required and an English replay available on its website.
Ascentage Pharma (NASDAQ: AAPG) appointed Dr. Faiçal Miyara as Chief Business Officer, overseeing global business development, and Jim Ziegler as Chief Commercial Officer, leading commercialization in the US and markets outside China. Both report to Chairman and CEO Dr. Dajun Yang.
The company links these hires to its advancing global registrational Phase III studies and a new phase of global expansion in hematologic malignancies. Dr. Miyara brings over 20 years of oncology business development experience at IO Biotech, Ipsen, Pfizer, ImClone Systems and Eli Lilly. Mr. Ziegler contributes more than 25 years of commercial leadership at Amgen, Gilead, Iovance Biotherapeutics and Geron.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) announced that Chairman and CEO Dr. Dajun Yang has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category among 60 global pharmaceutical leaders.
According to Ascentage Pharma, Dr. Yang co-founded the company in 2009 and has led development of a small‑molecule oncology pipeline including olverembatinib, the first third‑generation BCR‑ABL tyrosine kinase inhibitor approved in China, and lisaftoclax, approved in China in July 2025 for chronic lymphocytic leukemia and small lymphocytic lymphoma. The company has commercialized these two therapies in China, is conducting multiple global registrational Phase III trials—four cleared by both the FDA and EMA—and highlights lisaftoclax as the only Bcl‑2 inhibitor in a global registrational Phase III study for higher‑risk myelodysplastic syndromes. Ascentage Pharma also notes completion of a major business development transaction and its dual primary listings in Hong Kong and on Nasdaq.
Ascentage Pharma (NASDAQ:AAPG) presented 17 clinical updates at the EHA2026 Congress, highlighting key data on olverembatinib and lisaftoclax in CML, Ph+ ALL, CLL/SLL, AML, MDS, and CMML.
Results showed high response and MRD-negativity rates with generally manageable safety across multiple Phase Ib–III and real‑world studies.
Ascentage Pharma (NASDAQ:AAPG) reported first clinical data for MDM2‑p53 inhibitor alrizomadlin (APG-115) in pediatric solid tumors at ASCO 2026, as monotherapy and with Bcl‑2 inhibitor lisaftoclax.
The combination showed an ORR of 23.5% and DCR of 70.6% in 17 patients, with no DLTs and a manageable safety profile. Alrizomadlin is included in China’s pediatric “SPARK Plan” and remains investigational, not FDA approved.
Ascentage Pharma (NASDAQ:AAPG; HKEX:6855) reported Phase Ib data on olverembatinib (HQP1351) plus blinatumomab in relapsed/refractory Ph+ BCP-ALL and CML-LBP at ASCO 2026.
In this global study, 91% (10/11) achieved CR/CRi, 67% (8/12) reached BCR::ABL1 PCR ≤0.01%, and 80% (8/10) achieved MRD negativity ≤0.01%. Most adverse events were grade 1–2 and manageable.
Ascentage Pharma (NASDAQ:AAPG) reported updated Phase II data for olverembatinib (HQP1351) as second-line therapy in chronic-phase chronic myeloid leukemia (CML-CP) at ASCO 2026.
Among 42 evaluable patients, complete cytogenetic response reached 91.3% and major molecular response 60.9% at cycle 24, with a generally manageable safety profile.
Ascentage Pharma (NASDAQ:AAPG) reported new clinical data from six trials featuring olverembatinib, lisaftoclax, and alrizomadlin at ASCO 2026. Three abstracts received rapid oral slots and three poster presentations, covering leukemia, pediatric solid tumors, SDH-deficient tumors, and two ongoing global phase 3 registrational studies.